Stockscreener 앱 받기
6.07
1.17%
0.07
시간 외 거래:
5.97
-0.10
-1.65%
Imagenebio Inc 주식(IMA)의 최신 뉴스
ImageneBio Appoints Matt Robbins as General Counsel - The Manila Times
Enterprise value to revenue forward of ImageneBio, Inc. – NASDAQ:IMA - TradingView
Enterprise value to EBIT forward of ImageneBio, Inc. – BOATS:IMA - TradingView
IMA Stock Surges 24%, Breaks 50-DMA For First Time Since February – What's Driving The Rally? - Stocktwits
ImageneBio (IMA) prospectus supplement registers 2.5M shares for resale - Stock Titan
Price to earnings forward of ImageneBio, Inc. – NASDAQ:IMA - TradingView
Price to book forward of ImageneBio, Inc. – NASDAQ:IMA - TradingView
Price to sales forward of ImageneBio, Inc. – NASDAQ:IMA - TradingView
Price to sales forward of ImageneBio, Inc. – BOATS:IMA - TradingView
Price to earnings forward of ImageneBio, Inc. – BOATS:IMA - TradingView
Enterprise value to EBITDA forward of ImageneBio, Inc. – BOATS:IMA - TradingView
ImageneBio Announces Upcoming Transition in Financial Leadership - TipRanks
Imagenebio (NASDAQ: IMA) finance chief Robert Lally to step down - Stock Titan
Imagenebio, Inc. Announces Resignation of Robert Lally as Senior Vice President of Finance and Operations, Effective July 22, 2026 - marketscreener.com
ImageneBio, Inc. Actuals & Estimates (NASDAQ:IMA) - TradingView
IMA Forecast — Price Target — Prediction for 2027 - TradingView
IMAImageneBio Inc Latest SEC Filings - Finviz
ImageneBio Ord Shs (IMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ImageneBio Ord Shs (IMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ImageneBio Shareholders Back Directors and Governance Proposals - The Globe and Mail
ImageneBio stockholders approve equity plan amendment and elect directors By Investing.com - Investing.com India
ImageneBio Ord Shs (IMA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ImageneBio stockholders approve equity plan amendment and elect directors - Investing.com UK
ImageneBio Ord Shs (IMA) Institutional Confidence - TradingKey
ImageneBio Ord Shs (IMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ImageneBio Inc. (IMA) Slips 1.58% as Stock Nears Critical Support LevelFloat Adjusted Cap - newsline.com
IMA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Ramps Up R&DGuidance Downgrade Alert - dars.gov.et
IMA Q1 2026 Earnings: Wider-than-expected loss as EPS misses estimatesOne-Time Loss Impact - newsline.com
IMA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineNew Analyst Coverage - newsline.com
IMA Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing R&D InvestmentsDividend Earnings Report - newsline.com
ImageneBio Inc. (IMA) Q1 2026 Earnings: EPS Misses Estimates Amid Development Stage StatusMargin Expansion Trends - dars.gov.et
Ikena Oncology Inc stock (US4517401090): trading in United States halted as ImageneBio merger progre - AD HOC NEWS
Imagenebio Inc. Live Share Prices and Trades. IMA.US Live Streaming Share Prices. - London South East
IMA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Reports Wider LossRevenue Miss Report - dars.gov.et
ImageneBio (IMA) Holds Steady at $5.92 as Traders Eye Support and ResistanceMFI Oversold - dars.gov.et
ImageneBio CEO to present at 2026 Jefferies Global Healthcare Conference in New York - Pluang
ImageneBio CEO to speak at New York Jefferies healthcare conference June 4 - Stock Titan
IMA stock surges 24%, breaks 50-DMA for first time since February – what's driving the rally? - MSN
ImageneBio (IMA) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineCommunity Breakout Alerts - Newser
ImageneBio (IMA) Q1 2026 Results Fall Short — EPS $-0.95, Revenue $N/AExpert Stock Picks - Newser
ImageneBio (IMA) Q1 2026 Stumbles — EPS $-0.95 Misses TargetReturn On Assets - Newser
Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade - MSN
ImageneBio $30 million private placement ignites stock - MSN
1.17%
2.48%
자본화:
|
볼륨(24시간):